ライフサイエンスコーパス: CMV viremia

1 Twenty-three percent of patients developed CMV viremia.

2 S and cryptococcal meningitis had detectable CMV viremia.

3 T; group 2 comprised the 35 patients without CMV viremia.

4 uperior to conventional monitoring to detect CMV viremia.

5 of day of transplantation on posttransplant CMV viremia.

6 nous post-HCT NK cells, and not dependent on CMV viremia.

7 tor (VDR) pathway during different phases of CMV viremia.

8 s, and fewer Triplex-vaccinated patients had CMV viremia.

9 was associated with a 25% incidence of late CMV viremia.

10 0-week survival among those with and without CMV viremia.

11 December 2013; 32 (32%) tested positive for CMV viremia.

12 patient developed CMV-T cell responses post-CMV viremia.

13 of which can predict risk of progression to CMV viremia.

14 trols, suggesting an APC defect during acute CMV viremia.

15 ts, 23% (13 of 56) of those with significant CMV viremia.

16 survival rates among those with and without CMV viremia.

17 (92%) occurred in patents without antecedent CMV viremia.

18 C, hemoglobin <10 g/dL, lower CD4 count, and CMV viremia.

19 sity of immunosuppression after diagnosis of CMV viremia.

20 rom January 2007 to June 2011 for BKV and/or CMV viremia.

21 f worse outcomes in patients with late-onset CMV viremia.

22 0.02) were associated with a higher risk of CMV viremia.

23 stitution of thymopoiesis, but fail to clear CMV viremia.

24 s in humans, CD8 T cells proliferated during CMV viremia.

25 broadened over time despite the clearance of CMV viremia.

26 h belatacept presented a higher incidence of CMV viremia, a higher rate of first-line treatment failu

27 sociated with in-hospital mortality included CMV viremia (adjusted odds ratio [aOR] 3.2, 95% confiden

28 roviral therapy (HAART) led to a decrease in CMV viremia after a 90-day delay.

29 Patients treated for significant CMV viremia after HSCT were evaluated for CMV load befor

30 1 consisted of the 8 patients who developed CMV viremia after LT; group 2 comprised the 35 patients

31 milar to that of valganciclovir for clearing CMV viremia among recipients of hematopoietic-cell or so

32 rtality rates were 40% (23/58) in those with CMV viremia and 21% (11/53) in those without CMV viremia

33 week mortality was 40% (23/58) in those with CMV viremia and 21% (11/53) in those without CMV viremia

34 No relationship was found between changes in CMV viremia and changes in HIV RNA.

35 sease by 12 months, defined as CMV syndrome (CMV viremia and clinical or laboratory findings) or end-

36 We studied CMV viremia and clinical outcomes in 163 Kenyan children

37 t test was used to compare the proportion of CMV viremia and CMV retinitis in patients transplanted b

38 ntly better in the induction group; however, CMV viremia and CMV syndrome rates were significantly hi

39 BackgroundRefractory CMV viremia and disease are associated with significant

40 Donor CMV serostatus had no impact on CMV viremia and disease in the 2 cohorts.

41 CMV viremia and disease occurred in 27% and 4.5%, respec

42 characteristic curve analysis for predicting CMV viremia and disease showed a high area under the rec

43 or cytomegalovirus (CMV) serologic status on CMV viremia and disease when prophylactic granulocyte co

44 bserved; all severe manifestations combined (CMV viremia and disease) were significantly reduced amon

45 Patients with CMV viremia and HIV/AIDS infection or visual symptoms ar

46 The incidence of CMV viremia and of CMV disease was determined during the

47 All patients with CMV viremia and ophthalmologic examination during the st

48 e a relevant biomarker for assessing risk of CMV viremia and quantifying potential CMV-related graft

49 month period and compare this to the rate of CMV viremia and retinitis in the 4 years prior.

50 aft survival when compared with asymptomatic CMV viremia and those without CMV viremia (relative risk

51 ith valacyclovir also decreased the rates of CMV viremia and viruria, herpes simplex virus disease, a

52 The CS-CMVi was defined as CMV viremia and/or disease necessitating antiviral thera

53 gnificantly higher rates of cytomegalovirus (CMV) viremia and CMV syndrome occurred in those receivin

54 s viridians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that re

55 man herpesvirus (HHV)-7 and cytomegalovirus (CMV) viremia and the effects of oral and intravenous (iv

56 There was one case of cytomegalovirus (CMV) viremia and two cases of CMV disease (one pneumonit

57 a, (2) immune T-cell recovery anticipated by CMV viremia, and (3) no T-cell immune reconstitution des

58 At enrollment, 62/114 (54%) children had CMV viremia, and 20 (32%) were >=1000 IU/mL.

59 hich one screens for and treats asymptomatic CMV viremia, and universal antiviral prophylaxis.

60 CMV viremia as detected by PCR does not affect the progr

61 Cytomegalovirus (CMV) viremia, as measured by a hybrid capture assay, was

62 viremia (preemptive, N = 15) or detection of CMV viremia associated with a CMV syndrome (deferred, N

63 Neither patient had CMV viremia before onset of pneumonia.

64 for a circadian effect of transplantation on CMV viremia, but these novel results warrant confirmatio

65 tients, who had been previously analyzed for CMV viremia by polymerase chain reaction (PCR) for 12 we

66 om 35 transplant recipients with and without CMV viremia by using a microarray chip covering 847 hsa-

67 Twenty-five patients had CMV viremia (by shell vial cell culture assay) and/or ti

68 The primary endpoint was confirmed CMV viremia clearance at week 8 (primary hypothesis of n

69 ty margin, maribavir demonstrated comparable CMV viremia clearance during post-treatment follow-up, w

70 and valganciclovir, respectively) maintained CMV viremia clearance without tissue-invasive disease (a

71 ng/mL) and were even lower after periods of CMV viremia compared with the control group (48.3 3.5 ve

72 65 that predicted protection from subsequent CMV viremia (concordance index 0.88 [SE, 0.087]).

73 r pre-emptive valganciclovir for significant CMV viremia detected at predefined assessments through m

74 of antiviral therapy for early asymptomatic CMV viremia detected by surveillance testing), has not p

75 ncreasing Ab titers to human CMV, with human CMV viremia detected in approximately one-third of PWH a

76 MV(+) KTR (n = 112), stratified according to CMV viremia detection.

77 e range, 0.5-197 months) in whom significant CMV viremia developed (CMV level at PCR, >/=4000 copies/

78 CMV viremia developed a mean time of 102 ( 34) d post-HS

79 CMV viremia did not appear to boost CMV-specific immunit

80 ents after treatment of the first episode of CMV viremia/disease.

81 ral drug resistance should be suspected when CMV viremia (DNAemia or antigenemia) fails to improve or

82 Oral ganciclovir also prevented CMV viremia during prophylaxis (2/19 patients [11%] vs.

83 Recipients developed CMV viremia during the first month post-BMT.

84 Time to clearance of CMV viremia during treatment was significantly longer in

85 ne the relationship between cytomegalovirus (CMV) viremia during early infancy and clinical and labor

86 Eighty percent of CMV viremia episodes occurred before 120 days posttransp

87 sidered the "gold standard" for detection of CMV viremia, especially when transport of specimens over

88 c stem cell transplant patients, the risk of CMV viremia following ACV prophylaxis is associated with

89 t a median of 12 days (range, 3-57 days) and CMV viremia greater than 1000 copies/mL occurred in 20%

90 n models were used to identify correlates of CMV viremia >= 1000 IU/mL and estimate associations with

91 circumference < 12.5 cm were associated with CMV viremia >= 1000 IU/mL.

92 els were used to assess associations between CMV viremia >=1000 IU/mL and the risk of continued hospi

93 During the follow-up, CMV viremia >=1000 IU/mL occurred in only 4 of 33 patien

94 The primary endpoint was CMV viremia >=1000 IU/mL up to 1 y posttransplant.

95 CMV viremia >=1000 IU/mL was independently associated wi

96 Moreover, we found that only symptomatic CMV viremia had a significant negative impact on graft s

97 CMV viremia and 21% (11/53) in those without CMV viremia (hazard ratio 2.19, 95% confidence interval

98 CMV viremia and 21% (11/53) in those without CMV viremia (Hazard Ratio=2.19; 95%CI, 1.07-4.49; P=.03)

99 ere sufficient for reactivation of low-level CMV viremia, high-level viremia (>1,000 copies of CMV DN

100 ay to monitor the incidence and treatment of CMV viremia in a Cynomolgus macaque model of bone marrow

101 To date, no studies have assessed CMV viremia in children diagnosed with HIV in hospital.

102 We measured CMV viremia in HIV-exposed and -unexposed Kenyan childre

103 We identified a high prevalence of relapsing CMV viremia in IPF-LTRs compared with non-IPF-LTRs (69%

104 for immunological monitoring and predicting CMV viremia in pediatric HSCT.

105 ), and a CMV plasma PCR for the detection of CMV viremia in renal and bone marrow transplant recipien

106 It remains unclear whether CMV viremia in severely immunocompromised persons with c

107 It remains unclear whether CMV viremia in severely immunocompromised persons with c

108 in a significant and progressive decline in CMV viremia in the absence of specific anti-CMV therapy.

109 In a separate analysis, untreated isolated CMV viremia in the first CMV infection episode was follo

110 CMV viremia in the first year after pediatric primary lu

111 in may be a potential adjunctive therapy for CMV viremia in undernourished transplant recipients.

112 valence and risk factors of cytomegalovirus (CMV) viremia in patients infected with human immunodefic

113 Cytomegalovirus (CMV) viremia in persons with human immunodeficiency viru

114 sure to ganciclovir during prophylaxis, with CMV viremia incidence during and after treatment, CMV di

115 g-transplant recipients, we hypothesize that CMV viremia increases the risk of bronchiolitis oblitera

116 ter LT for chronic HCV, patients who develop CMV viremia incur a significantly greater risk of severe

117 We investigated whether short-term CMV viremia influences HCV recurrence, the number and gr

118 It is unknown whether concurrent CMV viremia is associated with mortality in other AIDS-r

119 It is unknown if concurrent CMV viremia is associated with mortality in other AIDS-r

120 CMV viremia is associated with significant dysregulation

121 Uncontrolled CMV viremia is associated with specific clusters of memo

122 The results indicate that CMV viremia is not an ideal marker to guide preemptive a

123 To study whether cytomegalovirus (CMV) viremia is a reliable marker of impending CMV disea

124 Cytomegalovirus (CMV) viremia is associated with mortality in severely il

125 Cytomegalovirus (CMV) viremia is common in human immunodeficiency virus (

126 CMI assessment shortly after the onset of CMV viremia may be useful to predict progression versus

127 CMV viremia may indirectly protect against subsequent BK

128 Cytomegalovirus (CMV) viremia may be associated with increased mortality

129 Cytomegalovirus (CMV) viremia may be associated with increased mortality

130 patients were given preemptive therapy with CMV viremia monitoring after transplantation.

131 sistant CMV infection including asymptomatic CMV viremia (n = 3), CMV syndrome (n = 1), and CMV pneum

132 sistant CMV infection including asymptomatic CMV viremia (n=3), CMV syndrome (n=1) and CMV pneumoniti

133 Neither CMV viremia nor CMV disease after OLT for HCV-related ci

134 rwent allogeneic HSCT; 13 patients (46%) had CMV viremia, not a statistically significant increase (P

135 CMV viremia occurred in three patients in the acyclovir

136 Clearance of CMV viremia occurs later and depends on the recovery of

137 lized adults with COVID-19 requiring oxygen, CMV viremia occurs within well-defined clinical risks an

138 variable associated with the development of CMV viremia (odds ratio [OR]=1.65; CI 1.03, 2.65) and IT

139 Among 609 recipients, 108 (17.7%) developed CMV viremia, of which 95 (88%) were asymptomatic, 5 (5%)

140 HAART suppressed CMV viremia only after a delay of several months.

141 hase I/II trials, we treated 67 subjects for CMV viremia or disease arising after HCT with adoptive t

142 The primary outcome was recurrence of CMV viremia or disease within 6 months of treatment disc

143 9-70) and did not differ by the presence of CMV viremia (P = .47).

144 g CMV viremia relative to the expression pre-CMV viremia (P = 0.012) but not TLR6/7/8 and the TLR-ada

145 ( 42.5%) relative to the VDR expression pre-CMV viremia (P = 0.035) and lagged in recovery following

146 9-70) and did not differ by the presence of CMV viremia (P=.47).

147 Univariate analysis demonstrated that CMV viremia (P=0.001), invasive fungal disease (P=0.0001

148 nt BKV viremia than patients with antecedent CMV viremia (P=0.003; hazard ratio, 2.05; 95% confidence

149 nts (68%) ultimately showed PCR evidence for CMV viremia (P=0.005).

150 CMV viremia parameters were compared between time catego

151 intravenously for 21 days upon detection of CMV viremia (preemptive, N = 15) or detection of CMV vir

152 The observed cytomegalovirus (CMV) viremia rate for patients at risk was low (15%), as

153 TLR) 2 mRNA was upregulated to 225.4% during CMV viremia relative to the expression pre-CMV viremia (

154 h asymptomatic CMV viremia and those without CMV viremia (relative risk, 3.5; 95% confidence interval

155 justment for HIV load and CD4(+) cell count, CMV viremia remained associated with an increased risk o

156 The first episode of CMV viremia requiring antiviral therapy was assessed in

157 were CMV events (CMV DNA level >=1250 IU/mL, CMV viremia requiring antiviral treatment, or end-organ

158 e-dependent, Cox proportional hazards model, CMV viremia (RR=8.6, 95% CI 1.8-39.7, P=0.0012), invasiv

159 For CMV viremia, syndrome and disease, the most common first

160 Cytomegalovirus (CMV) viremia that is resistant or refractory to the stan

161 which are potentially linked with control of CMV viremia to prevent graft rejection.

162 Incidence and persistence of CMV viremia under belatacept vs tacrolimus were compared

163 All HSCT recipients with significant CMV viremia underwent retinal examination weekly (inpati

164 may be overcome by novel methods to monitor CMV viremia using self-testing platforms.

165 Within a same episode, CMV viremia was 90% sensitive and 80% specific for predi

166 Increased CMV viremia was associated with a concomitant fall in Ka

167 CMV viremia was associated with an over 2-fold higher mo

168 ivariate analysis was used to assess whether CMV viremia was associated with BOS or death and retrans

169 Concurrent HHV-6 and CMV viremia was associated with earlier onset of HHV-6 v

170 Concurrent HHV-6 and CMV viremia was associated with earlier onset of HHV-6 v

171 In late-stage HIV-infected patients, CMV viremia was associated with lower functional status

172 CMV viremia was associated with over two-fold higher mor

173 A first episode of CMV viremia was associated with retransplantation or dea

174 In this nested observational study, CMV viremia was common in hospitalized children with HIV

175 Time to CMV viremia was delayed in the ganciclovir group; howeve

176 CMV viremia was detected by at least one method in 125 o

177 CMV viremia was detected in 31% of children, with levels

178 ese Thai patients with advanced HIV disease, CMV viremia was frequent, and CMV DNA >500 copies/mL pre

179 95% CI, 0.09-0.55; P = .001) when persistent CMV viremia was modeled.

180 CMV viremia was not significantly associated with mortal

181 CMV viremia was noted in 6 patients (all 4 D+/R- patient

182 Initial clearance of CMV viremia was observed in 14 of 17 patients (82%), and

183 The prevalence of CMV viremia was only 5.8% (1-10%).

184 CMV viremia was reduced in every case and eight patients

185 Assessment of CMV viremia was restricted to symptomatic cases in the r

186 ion was monitored through flow cytometry and CMV viremia was tracked via quantitative polymerase chai

187 The incidence of cytomegalovirus (CMV) viremia was 0.5 in the MUD group and 0.6 in the MMR

188 A total of 18 patients (7.7%) with CMV viremia were found to have CMVR.

189 The prevalence and level of CMV viremia were highest in children <2 years and lowest

190 Patients with CMV viremia were identified via International Classifica

191 The odds of CMV viremia were lower for prophylaxis (OR = 0.42; 95% C

192 y also expanded in the absence of detectable CMV viremia when both the donor and recipient were CMV s

193 Twelve patients experienced CMV viremia, whereas 31 developed CMV disease.

194 rplay of cytotoxic lymphocytes responding to CMV viremia, which are potentially linked with control o

195 A total of 234 patients with CMV viremia who underwent a screening dilated fundus exa

196 Four patients developed CMV viremia with clearance by 1.2 months, which correlat

197 nitiated after a median of three episodes of CMV viremia, with a mean peak viral load of 245,826 copi

198 investigator (investigator treated [IT]), or CMV viremia within 12 months of transplant in D+/R- tran